These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function. Dowling NM; Johnson SC; Gleason CE; Jagust WJ; Neuroimage; 2015 Jan; 105():357-68. PubMed ID: 25450107 [TBL] [Abstract][Full Text] [Related]
48. Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study. Vrillon A; Mouton-Liger F; Martinet M; Cognat E; Hourregue C; Dumurgier J; Bouaziz-Amar E; Brinkmalm A; Blennow K; Zetterberg H; Hugon J; Paquet C Alzheimers Res Ther; 2022 May; 14(1):71. PubMed ID: 35606871 [TBL] [Abstract][Full Text] [Related]
49. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677 [TBL] [Abstract][Full Text] [Related]
50. Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease. Shinohara M; Fujioka S; Murray ME; Wojtas A; Baker M; Rovelet-Lecrux A; Rademakers R; Das P; Parisi JE; Graff-Radford NR; Petersen RC; Dickson DW; Bu G Brain; 2014 May; 137(Pt 5):1533-49. PubMed ID: 24625695 [TBL] [Abstract][Full Text] [Related]
51. Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Mukaetova-Ladinska EB; Garcia-Siera F; Hurt J; Gertz HJ; Xuereb JH; Hills R; Brayne C; Huppert FA; Paykel ES; McGee M; Jakes R; Honer WG; Harrington CR; Wischik CM Am J Pathol; 2000 Aug; 157(2):623-36. PubMed ID: 10934165 [TBL] [Abstract][Full Text] [Related]
52. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Gouras GK; Tampellini D; Takahashi RH; Capetillo-Zarate E Acta Neuropathol; 2010 May; 119(5):523-41. PubMed ID: 20354705 [TBL] [Abstract][Full Text] [Related]
53. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia. Das S; Goossens J; Jacobs D; Dewit N; Pijnenburg YAL; In 't Veld SGJG; Teunissen CE; Vanmechelen E Alzheimers Res Ther; 2023 Mar; 15(1):62. PubMed ID: 36964594 [TBL] [Abstract][Full Text] [Related]
54. Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution. Vergara C; Ordóñez-Gutiérrez L; Wandosell F; Ferrer I; del Río JA; Gavín R Mol Neurobiol; 2015; 51(3):1206-20. PubMed ID: 24965601 [TBL] [Abstract][Full Text] [Related]
55. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies. Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322 [TBL] [Abstract][Full Text] [Related]
57. Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-β accumulation and independently accelerates the development of tau abnormalities. Tran HT; LaFerla FM; Holtzman DM; Brody DL J Neurosci; 2011 Jun; 31(26):9513-25. PubMed ID: 21715616 [TBL] [Abstract][Full Text] [Related]
58. New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer's disease. Park SA; Han SM; Kim CE Exp Mol Med; 2020 Apr; 52(4):556-568. PubMed ID: 32284537 [TBL] [Abstract][Full Text] [Related]
59. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease. Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185 [TBL] [Abstract][Full Text] [Related]